LeMaitre Vascular (NASDAQ:LMAT) Rating Increased to Buy at Stifel Nicolaus

LeMaitre Vascular (NASDAQ:LMAT) was upgraded by equities researchers at Stifel Nicolaus from a “hold” rating to a “buy” rating in a research report issued on Friday, Marketbeat reports. The firm presently has a $75.00 price target on the medical instruments supplier’s stock, up from their prior price target of $59.00. Stifel Nicolaus’ price target would suggest a potential upside of 14.57% from the company’s current price.

Other equities research analysts have also issued reports about the stock. KeyCorp began coverage on shares of LeMaitre Vascular in a research note on Tuesday, February 6th. They set a “sector weight” rating for the company. Barrington Research boosted their target price on shares of LeMaitre Vascular from $66.00 to $69.00 and gave the company an “outperform” rating in a research note on Wednesday, February 28th. Finally, StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Tuesday, April 16th. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $69.33.

LeMaitre Vascular Stock Up 3.9 %

Shares of NASDAQ LMAT opened at $65.46 on Friday. LeMaitre Vascular has a twelve month low of $44.27 and a twelve month high of $74.64. The firm has a market cap of $1.47 billion, a P/E ratio of 48.85, a PEG ratio of 2.82 and a beta of 0.87. The company has a 50 day moving average of $65.35 and a 200 day moving average of $58.11.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Tuesday, February 27th. The medical instruments supplier reported $0.38 earnings per share for the quarter, topping analysts’ consensus estimates of $0.36 by $0.02. The company had revenue of $48.90 million during the quarter, compared to analyst estimates of $49.01 million. LeMaitre Vascular had a net margin of 15.56% and a return on equity of 10.57%. The firm’s revenue for the quarter was up 19.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.25 EPS. As a group, equities analysts expect that LeMaitre Vascular will post 1.66 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Lawrence J. Jasinski sold 5,110 shares of the business’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $67.50, for a total transaction of $344,925.00. Following the completion of the sale, the director now owns 5,309 shares of the company’s stock, valued at approximately $358,357.50. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, CFO Joseph P. Pellegrino, Jr. sold 36,967 shares of the company’s stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $69.76, for a total value of $2,578,817.92. Following the completion of the transaction, the chief financial officer now owns 6,452 shares of the company’s stock, valued at approximately $450,091.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Lawrence J. Jasinski sold 5,110 shares of the company’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $67.50, for a total transaction of $344,925.00. Following the completion of the transaction, the director now directly owns 5,309 shares of the company’s stock, valued at approximately $358,357.50. The disclosure for this sale can be found here. Insiders sold a total of 114,036 shares of company stock valued at $7,873,749 in the last 90 days. Company insiders own 10.79% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Shaker Investments LLC OH boosted its holdings in LeMaitre Vascular by 1.3% in the 1st quarter. Shaker Investments LLC OH now owns 13,658 shares of the medical instruments supplier’s stock worth $906,000 after buying an additional 169 shares during the period. Exchange Traded Concepts LLC lifted its stake in LeMaitre Vascular by 0.8% in the 4th quarter. Exchange Traded Concepts LLC now owns 23,656 shares of the medical instruments supplier’s stock worth $1,343,000 after purchasing an additional 187 shares in the last quarter. Riverwater Partners LLC lifted its stake in LeMaitre Vascular by 2.5% in the 4th quarter. Riverwater Partners LLC now owns 8,216 shares of the medical instruments supplier’s stock worth $466,000 after purchasing an additional 198 shares in the last quarter. Albion Financial Group UT lifted its stake in LeMaitre Vascular by 5.6% in the 1st quarter. Albion Financial Group UT now owns 3,974 shares of the medical instruments supplier’s stock worth $264,000 after purchasing an additional 212 shares in the last quarter. Finally, Personal CFO Solutions LLC lifted its stake in LeMaitre Vascular by 6.4% in the 4th quarter. Personal CFO Solutions LLC now owns 5,574 shares of the medical instruments supplier’s stock worth $316,000 after purchasing an additional 336 shares in the last quarter. Institutional investors own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.